RHHBY - Roche Holding AG

Other OTC - Other OTC Delayed Price. Currency in USD

Roche Holding AG

Konzern-Hauptsitz
Grenzacherstrasse124
Basel 4070
Switzerland
41 61 688 11 11
http://www.roche.com

SectorHealthcare
IndustryDrug Manufacturers—General
Full Time Employees94,442

Key Executives

NameTitlePayExercisedYear Born
Dr. Severin SchwanCEO & Exec. DirectorN/AN/A1967
Dr. Alan HippeChief Financial & IT OfficerN/AN/A1967
Dr. Gottlieb A. KellerGen. Counsel & Corp. Sec.N/AN/A1954
Ms. Cristina A. WilburHead of Group HRN/AN/A1967
Dr. Karl MahlerHead of Investor RelationsN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Roche Holding AG engages in the diagnostics and prescription pharmaceuticals businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anaemia, anticoagulation therapy, bone, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid and liver disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus and infectious diseases. The company's diagnostic solutions include blood gas analysis; blood screening; cancer screening/monitoring; cardiac markers; cardiovascular testing; cholesterol and coagulation monitoring; coagulation routine and specialty testing; data management; diabetes monitoring and therapy; electrolytes analysis; emergency medicine; hemostasis, heterogeneous immunochemistry, homogeneous immuno assay, immunology, and infectious disease solutions; intensive care testing; monitoring anti platelet therapy; neonatal intensive care units; nucleic acid purification; PCR clinical diagnostics; physical fitness testing; platelet function testing; quality control services; real-time PCR diagnostic systems; urinalysis; and serum work area and workflow solutions. In addition, it offers gene expression, gene sequencing, and real time PCR systems for researchers. The company licenses its products or technologies to third parties. Roche Holding AG has collaboration agreements with San Francisco-based Syapse; KAHR Medical; Synlogic, Inc.; and Dicerna Pharmaceuticals, Inc. The company was founded in 1896 and is headquartered in Basel, Switzerland.

Corporate Governance

Roche Holding AG’s ISS Governance QualityScore as of October 4, 2019 is 6. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 1; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.